Value Health Receives Early Termination of Hart-Scott-Rodino Waiting Period for Diagnostek Acquisition

Strategic Insights -

Value Health, Inc., a leading provider of specialty managed care benefit programs and health care information services, has announced that the Federal Trade Commission (FTC) has granted early termination of the Hart-Scott-Rodino waiting period for its acquisition of Diagnostek, Inc. This development enables Value Health to move forward with the transaction, pending approval from the Securities and Exchange Commission (SEC) and shareholder approval from both companies. Value Health expects to close the deal in late June or early July. The acquisition will combine the capabilities of ValueRx and Diagnostek, creating the leading independent Prescription Benefit Management (PBM) company in the country.

Key Takeaways:

  • Value Health's acquisition of Diagnostek has received early termination of the Hart-Scott-Rodino waiting period from the FTC.
  • The company anticipates closing the transaction in late June or early July, pending approval from the SEC and shareholder approval from both companies.
  • The combined company will be the leading independent PBM in the country, with capabilities from both ValueRx and Diagnostek.
  • Value Health provides services to more than 64 million people, including 58 of the nation's largest corporations.
  • The acquisition will enhance Value Health's specialty managed care benefit programs, including prescription drugs, mental health, and workers' compensation.
  • Value Health's health care information services include clinically based precertification and claims review, provider profiling, claims cost analysis, and disease management program development.

Statistics:

  • Value Health serves over 64 million people.
  • The company has 58 of the nation's largest corporations as customers.
  • The acquisition is expected to close in late June or early July.
  • Value Health's health care information services include clinically based precertification and claims review for over 64 million people.
  • The combined company will provider services to 64 million people.

Sources:

  • PR Newswire, "Value Health, Inc. Announces Acquisition of Diagnostek, Inc. Has Received Early Termination of Hart-Scott-Rodino Waiting Period" (May 3, 1995)
  • Value Health, Inc. press release, "Value Health, Inc. to Acquire Diagnostek, Inc." (No date provided)